At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 21 enrolled
Drug / intervention
BKM120drug
Likely dose
BKM120 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A CR-UK Phase I Study of BKM120 in Patients With Non-small Cell Lung Cancer (NSCLC) Receiving Thoracic Radiotherapy
In Brief
A Phase 1 clinical trial evaluating BKM120 for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 21 participants across 1 site.
Detailed Summary
This study will test whether a drug called BKM120/buparlisib is a safe and effective treatment when given to lung cancer patients having radiotherapy treatment. The trial will identify which of three possible doses of buparlisib is best to give with lung radiotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited Kingdom
CollaboratorsCancer Research UK, Novartis
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedMay 2014
Primary CompletionOct 2017
TodayJul 2026
First PostedMay 1, 2014
Enrollment StartApr 1, 2013
Primary CompletionOct 17, 2017
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 12.2 years ago
Interventions
BKM120drug
Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.